Envision

Company News

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Findings support saRNA as a therapeutic strategy to compensate dystrophin’s function by upregulating UTRN expression…

EnvisionNovember 2, 2023

Presentations

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

Event: 2023 Annual OTS Conference (Barcelona Spain) View Poster

EnvisionNovember 2, 2023

Presentations

SCAD: a platform technology for CNS delivery of duplex RNA by intrathecal administration (Poster)

Event: 2023 Annual OTS Conference (Barcelona Spain) View Poster

EnvisionNovember 2, 2023

Company News RAG-17

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically validate Ractigen’s…

EnvisionJune 10, 2023

Presentations RAG-01 Presentation

Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (Abstract)

Event: 2023 American Society of Clinical Oncology Meeting (Chicago) View Abstract

EnvisionJune 7, 2023

Presentations RAG-17 Presentation

siRNA-ACO is a convenient phosphoramidite-based conjugate that enables RNAi in the CNS via local administration with superior efficacy in the treatment of ALS rodent models (Poster)

Event: 2023 TIDES USA (San Diego) View Poster

EnvisionMay 12, 2023

Presentations RAG-17 Presentation

Local administration of a novel siRNA conjugate (siRNA-ACO) into the CNS extends survival and improves motor function in the SOD1G93A mouse model for ALS (Poster)

Event: 2023 TIDES ASIA (Kyoto, Japan) View Poster

EnvisionMarch 10, 2023

Company News RAG-17

Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…

EnvisionMarch 3, 2023

Company News Homepage News

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…

EnvisionJanuary 27, 2022

Company News Homepage News

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…

EnvisionFebruary 10, 2021

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster)

SCAD: a platform technology for CNS delivery of duplex RNA by intrathecal administration (Poster)

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (Abstract)

siRNA-ACO is a convenient phosphoramidite-based conjugate that enables RNAi in the CNS via local administration with superior efficacy in the treatment of ALS rodent models (Poster)

Local administration of a novel siRNA conjugate (siRNA-ACO) into the CNS extends survival and improves motor function in the SOD1G93A mouse model for ALS (Poster)

Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

Join Us

CONTACT US

Follow Us